

Barcelona, July 1st 2021

OTHER RELEVANT INFORMATION

Almirall and Kaken Pharmaceutical enter into a License and Distribution Agreement for European Rights to the topical formulation of efinaconazole

In accordance with Securities Markets Law approved Almirall, S.A. (“Almirall”) announce the following:

Kaken Pharmaceutical grants Almirall the exclusive right for the development and commercialization of the topical formulation efinaconazole in Europe.

This active principle, a triazole antifungal compound discovered by Kaken Pharmaceutical, is indicated for the treatment of onychomycosis, a fungal infection of the nail. Since it has low binding affinity with keratin, the main component of nails, it has superior nail-penetrating properties.

The product has been marketed in Japan since 2014 under the trade name of Clenafin[®]. It has also been launched in the United States, Canada, Korea, Taiwan, Hong Kong and Macau by Kaken’s partner companies under the trade name of Jublia[®].

Under the agreement, Kaken Pharmaceutical receives an upfront cash payment and has the potential to receive milestone payments and royalties on the net sales of the product. Almirall plans to have a pre-submission meeting with regulatory authorities to prepare the approval of the product in Europe within the next 12 months.

Yours sincerely,

Pablo Divasson del Fraile
Investor Relations Department
investors@almirall.com